سعر نوفارينج حلقة مهبلية 2026

NuvaRing - combined hormonal contraceptive vaginal ring (estrogen/progestin) containing 11.7 mg etonogestrel and 2.7 mg ethinylestradiol, used by women to prevent pregnancy; one ring per pack in Egypt.

• Prevention of pregnancy in females of reproductive age.Population: Females of reproductive ageDailyMed (U.S. National Library of Medicine)
• Contraception in women of fertile age (safety and efficacy established in women aged 18 to 40 years).Population: Women of fertile ageelectronic medicines compendium (emc)

• Common adverse reactions (>=2%) in clinical trials: vaginitis (13.8%), headache including migraine (11.2%), mood changes (6.4%), device-related events such as expulsion, discomfort or foreign-body sensation (6.3%), nausea/vomiting (5.9%), vaginal discharge (5.7%), weight increase (4.9%), vaginal discomfort (4.0%), breast pain/tenderness (3.8%), dysmenorrhoea (3.5%), abdominal pain (3.2%), acne (2.4%) and decreased libido (2.0%). Serious reactions included deep vein thrombosis, anxiety, cholelithiasis and vomiting. Post-marketing: hypersensitivity (anaphylaxis, angioedema), stroke, arterial thromboembolic events, chloasma, urticaria, penile reactions in male partners, galactorrhoea, ring breakage and associated vaginal injury.International label, same product · DailyMed (U.S. National Library of Medicine)
• The most frequently reported undesirable effects in clinical trials were headache, vaginal infections and vaginal discharge, each reported by 5-6% of women. CHC use is associated with an increased risk of arterial and venous thrombotic and thromboembolic events (myocardial infarction, stroke, transient ischaemic attacks, venous thrombosis and pulmonary embolism).International label, same product · electronic medicines compendium (emc)

• Contraindicated in women at high risk of arterial or venous thrombotic disease (e.g. smokers over 35; current or past DVT/PE; cerebrovascular or coronary artery disease; thrombogenic valvular or rhythm disease; inherited or acquired hypercoagulopathies; uncontrolled hypertension; diabetes with vascular disease; migraine with aura or focal neurological symptoms; any migraine in women over 35); liver tumours or liver disease; undiagnosed abnormal uterine bleeding; pregnancy; current or past breast cancer; hypersensitivity including anaphylaxis and angioedema to any component; and use of hepatitis C combinations containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir.International label, same product · DailyMed (U.S. National Library of Medicine)
• CHCs should not be used in: presence or risk of venous thromboembolism (current or past VTE, hereditary or acquired predisposition such as APC resistance/factor V Leiden or antithrombin III, protein C or protein S deficiency, major surgery with prolonged immobilisation, multiple risk factors); presence or risk of arterial thromboembolism (current or past ATE or prodromal conditions, cerebrovascular disease, hyperhomocysteinaemia or antiphospholipid antibodies, migraine with focal neurological symptoms, diabetes with vascular symptoms, severe hypertension, severe dyslipoproteinaemia); pancreatitis with severe hypertriglyceridaemia; severe hepatic disease until liver values normalise; liver tumours; sex-steroid-influenced malignancies of the genital organs or breasts; undiagnosed vaginal bleeding; hypersensitivity to the active substances or excipients; and concomitant use with ombitasvir/paritaprevir/ritonavir and dasabuvir, glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir.International label, same product · electronic medicines compendium (emc)

• Boxed warning: cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive use; the risk increases with age (particularly over 35) and number of cigarettes smoked. Women over 35 who smoke should not use NuvaRing.International label, same product · DailyMed (U.S. National Library of Medicine)
• Stop NuvaRing if an arterial or venous thrombotic event occurs, or with unexplained loss of vision, proptosis, diplopia, papilloedema or retinal vascular lesions. If feasible, stop at least 4 weeks before and through 2 weeks after major surgery and during prolonged immobilisation; start no earlier than 4 weeks after delivery in women who are not breastfeeding.International label, same product · DailyMed (U.S. National Library of Medicine)
• Toxic shock syndrome has been reported in NuvaRing users (in some cases with tampon use); a causal relationship has not been established. Consider TSS if signs or symptoms occur and evaluate promptly.International label, same product · DailyMed (U.S. National Library of Medicine)

• Enzyme inducers (e.g. phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, St John's wort)CYP3A4-inducing drugs or herbal products may lower CHC concentrations, reducing contraceptive effectiveness or causing breakthrough bleeding; use an alternative non-hormonal or back-up method during use and for 28 days after stopping the inducer. Diaphragms, cervical caps and female condoms are not recommended as back-up methods with NuvaRing.DailyMed (U.S. National Library of Medicine)
• Strong or moderate CYP3A4 inhibitors (e.g. itraconazole, voriconazole, fluconazole, ketoconazole, grapefruit juice); atorvastatin; ascorbic acid; acetaminophenMay increase plasma estrogen and/or progestin concentrations (atorvastatin increases ethinylestradiol AUC by about 20-25% with certain CHCs).DailyMed (U.S. National Library of Medicine)
• Hepatitis C combinations: ombitasvir/paritaprevir/ritonavir with or without dasabuvir; glecaprevir/pibrentasvirContraindicated with ombitasvir/paritaprevir/ritonavir (± dasabuvir) because of ALT elevations; glecaprevir/pibrentasvir may also increase the risk of ALT elevations.DailyMed (U.S. National Library of Medicine)

• Contraindicated during pregnancy because there is no need for pregnancy prevention in a pregnant woman. Epidemiologic studies and meta-analyses have not shown an increased risk of genital or non-genital birth defects after maternal exposure to low-dose CHCs before conception or in early pregnancy. Discontinue if pregnancy is confirmed.International label, same product · DailyMed (U.S. National Library of Medicine)
• NuvaRing is not indicated during pregnancy; if pregnancy occurs with the ring in situ, remove the ring. Extensive epidemiological studies showed neither an increased risk of birth defects in children of women who used COCs before pregnancy nor a teratogenic effect with inadvertent use in early pregnancy; clinical experience of pregnancies exposed to NuvaRing has not been reported.International label, same product · electronic medicines compendium (emc)
• Small amounts of contraceptive steroids and/or metabolites, including etonogestrel and ethinylestradiol, pass into human milk; harmful effects in breastfed infants have not been observed. CHCs can reduce milk production; when possible use non-estrogen contraception until the child is weaned.International label, same product · DailyMed (U.S. National Library of Medicine)

• Etonogestrel: Combined hormonal contraception suppresses gonadotropins, mainly inhibiting ovulation; it also changes cervical mucus (hindering sperm entry) and the endometrium (reducing the likelihood of implantation).
• Ethinylestradiol: Combined hormonal contraception suppresses gonadotropins, mainly inhibiting ovulation; it also changes cervical mucus (hindering sperm entry) and the endometrium (reducing the likelihood of implantation).